Core Viewpoint - Theralase Technologies Inc. is hosting a conference call on November 19, 2025, to update investors on the interim data from its Phase II clinical study for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, along with financial and operational results for Q3 2025 [1][3]. Study II Update - As of November 7, 2025, Theralase is on track to complete enrollment in Q4 2025, with data lock and regulatory submissions expected in Q1 2027 [3]. - 88 patients have been treated, representing 97.8% of the targeted enrollment of 90 patients [6]. - 64.3% (54 out of 84) of patients achieved a Complete Response (CR) at any point, while 72.6% (61 out of 84) achieved a Total Response (TR) [6]. - At the 450-day assessment, 40% (18 out of 45) maintained a CR, and 42.2% (19 out of 45) maintained a TR, indicating durability of response [6]. Financial Update - Revenue decreased by 5% to $590,573 from $622,984, while the cost of sales decreased by 10% to $299,743, representing 51% of revenue [14]. - Gross margin remained stable at $290,830, which is 49% of revenue [14]. - Selling expenses decreased by 18% to $212,421, while administrative expenses increased by 12% to $1,444,687 [14]. - Research and development expenses increased by 1% to $2,116,540, reflecting increased activity for Study II [14]. - The net loss increased by 3% to $3,435,145, including $708,521 in non-cash expenses [14]. - The company raised $672,627 via a non-brokered private placement and has $280,000 in outstanding short-term loans at 15% interest as of November 7, 2025 [14].

Company Overview - Ryder System, Inc. is a leading provider of logistics and transportation solutions, focusing on fleet management and supply chain sectors [6] - The company operates a diversified business model across three segments: Fleet Management Solutions, Supply Chain Solutions, and Dedicated Transportation Solutions [9] - Ryder generates revenue from leasing, rental, maintenance, and value-added logistics services, serving a broad customer base in North America and internationally [9] Financial Performance - As of November 14, 2025, Ryder's stock price was $170.49, with a market capitalization of $6.88 billion [4] - The company reported a revenue of $12.68 billion and a net income of $502 million for the trailing twelve months (TTM) [4] - Ryder's third-quarter earnings rose 2% year over year to $3.33 per share, marking the fourth consecutive quarter of earnings growth on a per-share basis [10] Recent Developments - HG Vora Capital Management, LLC sold 300,000 shares of Ryder, resulting in a $37.77 million decrease in the fund's position value, reducing its stake to 8.56% of reportable assets under management (AUM) [2][8] - Despite the sale, Ryder remains the fifth largest holding in HG Vora's portfolio, with a total of 335,000 shares valued at $63.19 million [2][8] - Ryder's stock has fallen by 9.6% since the end of September, underperforming the S&P 500 by 8.82 percentage points [7][8] Market Conditions - The freight market conditions have been challenging this year, yet Ryder has managed to grow its business [10] - Outsourcing logistics to companies like Ryder is increasingly attractive for smaller businesses that cannot manage their own fleets [11] - Ryder has maintained dividend payments for over 49 years, with a recent 12% increase in its payout to $0.81 per share, offering a yield of 2.1% at recent prices [11]

Core Insights - The company reported record revenue of $1.2 million for Q3 2025, marking a 32% year-over-year increase from $0.9 million in Q3 2024 [1][1][1] - The growth is attributed to record volume in Catamaran® SI Joint Fusion System procedures and the introduction of SImmetry® SI Joint Fusion Product Sales [1][1][1] - The launch of SImmetry®+ alpha in Q4 2025 is expected to enhance the strategic portfolio [1][1][1] - The company has established a foundation for sustained growth through portfolio diversification, commercial expansion, and operational alignment [1][1][1] - Following the quarter end, the company announced a PIPE financing with supportive investors, raising total gross proceeds of $2.85 million [1][1][1]

Core Insights - Greene Concepts Inc. is expanding its product line by introducing two new sustainable packaging formats, Tetra Prisma and Tetra Top, both in 16.9-ounce sizes [1] - The new eco-friendly packaging aims to enhance the company's market reach, particularly in sectors such as hotels, resorts, and cruise lines, which are increasingly moving away from plastic bottles [1] Company Overview - Greene Concepts Inc. operates a 60,000-square-foot bottling facility located in Marion, North Carolina [1] - The company is known for producing the premium artesian spring water brand Be Water™ [1] Industry Trends - There is a growing trend among hospitality sectors, including hotels and cruise lines, to adopt sustainable practices by reducing the use of plastic bottles [1]

Core Insights - Dogwood Therapeutics, Inc. has successfully enrolled the first 100 patients in its ongoing HALT-CINP Phase 2b CINP trial, indicating progress in its clinical development efforts [1] - The continued low early termination rate among the first 80 study completers suggests that both Halneuron® and placebo treatment have been well tolerated, reflecting positively on the safety profile of the treatments being tested [1] - An interim analysis is scheduled for the fourth quarter of 2025, focusing on patients who have completed or been terminated from the four-week study, which will provide insights into the trial's efficacy and safety [1]

Core Insights - Nexscient, Inc. has formed a strategic alliance with Tekcapital, plc to leverage cutting-edge university research for AI solutions [1] Company Overview - Nexscient, Inc. is recognized as a leading innovator in artificial intelligence applications and intelligent enterprise solutions [1] - Tekcapital, plc is identified as a UK intellectual property investment group and technology transfer company [1] Strategic Objectives - The collaboration aims to identify and acquire transformative intellectual property assets from prominent global research institutions [1]

Core Insights - Delivra Health Brands reported a 1% increase in net revenue for Q1 2026, reaching $3,207 thousand, driven by an 8% growth in Dream Water® sales and a 9% increase in LivRelief™ Non-Infused sales, despite a significant decline in licensed LivRelief™ Infused sales [5][6][10] - The company experienced a gross profit of $1,501 thousand with a gross profit margin of 47%, down from 51% in the same period last year, attributed to higher sales fees and changes in customer and product mix [5][6] - Adjusted EBITDA improved to $56 thousand from $16 thousand year-over-year, reflecting a $40 thousand increase due to higher sales volume and reduced sales and marketing expenses [10][8] Financial Performance - Net revenue for Q1 2026 was $3,207 thousand, compared to $3,163 thousand in Q1 2025, marking a $44 thousand increase [5][6] - Gross profit decreased to $1,501 thousand from $1,598 thousand, with a gross profit margin of 47% compared to 51% in the previous year [5][6] - Total expenses excluding non-cash items were $1,447 thousand, down 10% from $1,607 thousand in Q1 2025, primarily due to reduced sales and marketing expenses [10][7] Sales Growth - Dream Water® sales grew by 8% in the U.S. and Canada, while e-commerce sales for Dream Water® surged by 74% compared to the same quarter last year [5][6] - LivRelief™ experienced a 9% growth in sales, with e-commerce sales increasing by 16% [5][6] - The company anticipates a return to growth for the licensed LivRelief™ Infused segment in the second half of fiscal 2026 following a transition to a new distribution partner [2][5] Management Strategy - The management emphasized the importance of innovation, marketing, and channel diversification in driving recurring consumer demand [2] - Plans for new product launches with strategic customers are set for the second half of fiscal 2026 to enhance market coverage and customer base [2]

Core Insights - The company has launched a nationwide Laundry Concierge licensing program aimed at creating a scalable pickup-and-delivery model for laundromats [1] - This program is designed to utilize unattended laundromats during off-peak hours while also supporting attended laundromats facing increased order volumes [1] Company Overview - Advanced Licensing is a division of MainStreetChamber Holdings, Inc. and is focused on expanding licensing opportunities in the laundry business sector [1] - The initiative targets individuals looking to start or expand their pickup-and-delivery laundry businesses [1]

Core Insights - Smart Eye has developed the first production-ready driver monitoring feature that can detect alcohol impairment in real time [1] - The feature has been recognized as a CES 2026 Innovation Awards® Honoree in the Vehicle Tech & Advanced Mobility category [1] Company Overview - Smart Eye is a leader in AI-based driver monitoring and in-cabin sensing technologies [1] - The company is publicly traded under multiple ticker symbols: STO:SEYE, OTC PINK:SMTEF, and FRA:SE9 [1]

Core Insights - Envoy Medical has enrolled the first three patients in the final stage of the pivotal clinical trial for the Acclaim® cochlear implant, indicating strong market interest and potential for commercialization [1][3][4] Company Overview - Envoy Medical, Inc. is a hearing health company focused on innovative technologies for hearing loss, including the fully implanted Acclaim® cochlear implant and the Esteem® active middle ear implant [5][6] - The Acclaim cochlear implant is designed to operate without external components, utilizing a novel sensor to capture sound, which differentiates it from traditional cochlear implants [2][6] Clinical Trial Progress - The final stage of the clinical trial will involve a total of 46 patients, with 43 spots remaining after the initial three enrollments [3] - The trial is being conducted at seven investigational sites across the United States, with additional surgeries already scheduled and many potential participants in the screening process [3][4] Market Demand - There is significant demand for the fully implanted cochlear device, as indicated by the rapid patient enrollment and interest from individuals with severe hearing loss [3][4] - The CEO of Envoy Medical emphasized the urgency to meet patient needs and the strong product-market fit, which could lead to faster FDA submission and commercialization [3][4] Regulatory Status - The Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a pivotal clinical trial [4][7]